Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CADI-R502
- Development stage
- Preclinical
- Lead developer
- Bio-Modeling Systems
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
CADI-R502 is a therapeutic program developed by Bio-Modeling Systems (BMSystems) using their proprietary Computer Assisted Deductive Integration (CADI) platform. The program was specifically designed to "rescue" the clinical development of a failed Phase III drug candidate in oncology, identified as **oblimersen** (Genasense), for the treatment of **metastatic melanoma**. By modeling the complex biological pathways and mechanisms of resistance, CADI-R502 identified the reasons for the clinical failure of oblimersen in unselected populations and proposed a revised therapeutic protocol. The model highlighted the role of specific biomarkers and pathways, particularly those involving **Bcl-2**-mediated apoptosis, to optimize patient selection and treatment efficacy. The program aims to reposition the Bcl-2 antisense oligonucleotide by identifying responsive patient subgroups or synergistic combinations that circumvent immune evasion and metabolic resistance mechanisms.
- Other names
- CADI-R502-Bio-Modeling Systems-OncologyCADI-R-502-Bio-Modeling Systems-OncologyCADI-R 502-Bio-Modeling Systems-Oncology
Beyond the preview
Go deeper on CADI-R502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CADI-R502.